Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
281-300 of 2,120 trials

Teicoplanin Dosing: Optimized vs. Standard Care

We are studying whether a new dosing method for teicoplanin helps patients achieve better treatment results compared to standard dosing. This trial looks at how quickly patients reach the right drug levels and their overall recovery.

Sepsis1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

E. coli Urinary Tract Infection: Pivmecillinam Treatment

We are studying whether an oral medication called pivmecillinam is as effective as standard treatments for E. coli urinary tract infections. This trial will also assess safety and other health effects.

Febrile Urinary Tract Infection>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesUrology

Follicular Lymphoma: Tisagenlecleucel vs. Standard Care

We are studying a new treatment called tisagenlecleucel for adults with relapsed or refractory follicular lymphoma. The goal is to see if it helps patients live longer and respond better than current standard treatments.

Follicular Lymphoma>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Polycystic Ovary Syndrome: Letrozole vs. Gonadotropins for Insemination

We are studying whether letrozole can be a better option than gonadotropins for achieving pregnancy in women with polycystic ovary syndrome. The trial will also examine miscarriage rates and treatment responses.

Insemination in Patients with Polycystic Ovary Syndrome>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesEndocrinologyGynecology and Obstetrics

HER2-Positive Metastatic Cancer: Trastuzumab Emtansine Study

We are providing ongoing treatment with trastuzumab emtansine for patients who previously benefited from this therapy. The study aims to assess the safety of long-term use, either alone or with other cancer treatments.

Metastatic Breast CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Fish Oil for Recovery in High-Risk Heart Surgery Patients

We are studying whether an intravenous fish oil treatment can prevent atrial fibrillation and improve recovery in patients undergoing high-risk cardiac surgery. This trial compares the fish oil treatment to a placebo.

Critical Illness3-6 monthsEfficacy phase (II)Investigational MedicinesCardiologyInternal Medicine

Alpha-1 Antitrypsin Deficiency: Fazirsiran Treatment Study

We are investigating the long-term safety of fazirsiran for people with liver disease related to Alpha-1 Antitrypsin Deficiency. The study will also look at how this treatment affects liver health over time.

Alpha-1 Antitrypsin Deficiency3-6 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHepatologyPulmonology

Preventing Postoperative Pain in Children: Locoregional Analgesia Study

We are studying whether locoregional analgesia can help reduce long-term pain after orthopedic surgery in children. The trial compares pain levels and recovery outcomes between different pain management methods.

Postoperative Pain>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOrthopedics and TraumatologyOtolaryngology

Metastatic Non-Small Cell Lung Cancer: Pembrolizumab with Sacituzumab Govitecan

We are studying whether combining pembrolizumab with sacituzumab govitecan improves survival and quality of life for patients with metastatic non-small cell lung cancer. This trial compares the combination treatment to pembrolizumab alone.

Metastatic Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Hereditary Angioedema: OCTA-C1-INH Treatment Study

We are studying a new intravenous treatment for people with hereditary angioedema to see if it effectively relieves symptoms during acute attacks. The trial includes adolescents and adults, and also looks at safety and quality of life.

Hereditary Angioedema1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyHematology

Pembrolizumab for Progressive Multifocal Leukoencephalopathy in Immunocompromised Patients

We are studying whether Pembrolizumab can help reduce the JCV viral load in the cerebrospinal fluid of immunocompromised patients with PML. This trial aims to understand its effects on neurological health and overall survival.

Progressive Multifocal Leukoencephalopathy (PML)6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesNeurology

MK-2870 vs Chemotherapy for Advanced Lung Cancer

We are studying a new treatment, MK-2870, for patients with advanced nonsquamous non-small cell lung cancer who have specific genetic mutations. The goal is to see if it works better than standard chemotherapy options.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Investigational MedicinesOncology

Advanced Non-Small Cell Lung Cancer: Zipalertinib with Chemotherapy

We are studying whether adding zipalertinib to standard chemotherapy helps patients with advanced non-small cell lung cancer who have a specific genetic mutation. This trial compares the effects of the combination treatment to chemotherapy alone.

Non-Small Cell Lung Cancer6-12 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Staphylococcus aureus Bacteremia: SNAP Trial

We are testing various treatment options for patients with Staphylococcus aureus bacteremia to see how they impact survival and other health outcomes. This study aims to improve care for those affected by this serious infection.

Staphylococcus aureus Bacteremia3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Liver Surgery: Octreotide Study

We are investigating whether octreotide can reduce blood loss and improve stability during laparoscopic liver surgery. This study will help us understand its effects compared to a placebo.

Laparoscopic Hepatectomy Surgery>2 yearsEfficacy phase (II)Standard MedicinesHepatologyInternal MedicineOtolaryngology

Acute Brain Injury: Apomorphine and Psilocybin Study

We are exploring the safety of two medications in patients who are unresponsive in the ICU due to brain injury. The goal is to find effective doses while monitoring for any side effects.

Coma and Disorders of Consciousness3-6 monthsSafety phase (I)Investigational MedicinesNeurologyPsychiatry

Metastatic Breast Cancer: Treatment Combinations Study

We are evaluating the effectiveness and safety of various treatment combinations for patients with metastatic breast cancer. This study aims to find better options for managing the disease.

Metastatic Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Atopic Dermatitis in Children: Tralokinumab Treatment

We are studying whether a new treatment with tralokinumab and topical steroids helps children aged 2 to under 12 and infants aged 6 months to under 2 manage moderate-to-severe atopic dermatitis better than a placebo. The trial also looks at how this treatment affects daily life and skin health.

Atopic Dermatitis1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Gastroesophageal and Pancreatic Cancer: New Imaging Technique

We are testing a new PET/CT imaging method to see if it improves cancer diagnosis and staging for patients with gastroesophageal and pancreatic cancer. This study aims to enhance comfort and effectiveness compared to standard imaging.

Pancreatic and Gastroesophageal CancerEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Efepoetin Alfa for Anemia in Chronic Kidney Disease on Dialysis

We are studying whether efepoetin alfa can effectively manage anemia in patients with chronic kidney disease on dialysis, compared to another treatment. This trial will also assess safety and quality of life for participants.

Anemia of Chronic Disease1-2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyNephrology